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REVIEW ARTICLE
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Therapies in the Second-Line Setting for Large B-cell
Lymphoma: A Game Changer?
Razan Mohty a, Muhamad Alhaj Moustafa a, Mahmoud Aljurf b,
Hemant Murthy a, Mohamed A. Kharfan-Dabaja a,*
a
b

Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA
Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

Abstract
Chimeric antigen receptor T-cell (CAR T) therapy has been proven effective in the third-line (and beyond) setting in
patients with large B-cell lymphoma (LBCL). Until recently, high-dose chemotherapy followed by autologous hematopoietic cell transplantation (auto-HCT) was considered the standard of care in the second-line setting in patients
demonstrating an objective response before the procedure. The ZUMA-7 and TRANSFORM studies showed the beneﬁt
of axicabtagene ciloleucel and lisocabtagene maraleucel, respectively, in patients refractory to or relapsing within 12
months of ﬁrst-line anthracycline-based chemoimmunotherapy. However, a third trial (BELINDA study) using tisagenlecleucel failed to show a beneﬁt in the same setting compared to standard salvage chemoimmunotherapy followed
by auto-HCT. Several differences exist between these trials, including trial designs, patient population, crossover
permissibility, bridging therapy, and end-point deﬁnitions. In this review, we summarize the current evidence for the
treatment of patients with LBCL in the third line and beyond and standard treatment in the second line before CAR T
therapy approval and interpret outcomes of the three trials examining the role of CAR T therapy in the second line and
their impact in reshaping future practice.
Keywords: Chimeric antigen receptor T-cell therapy, Second line, Large B-Cell lymphoma

1. Introduction

H

igh-dose therapy (HDT) followed by autologous hematopoietic cell transplantation (autoHCT) represents the standard treatment option for
patients with large B-cell lymphomas (LBCLs) that
relapse after frontline anthracycline-based chemoimmunotherapy and demonstrate an objective
response to platinum-based second-line therapy
[1,2]. Approximately 50% of cases are treated with
auto-HCT [1,2]. Unfortunately, for patients who
receive auto-HCT in less than a partial response
(PR), the efﬁcacy of auto-HCT is limited, with an
anticipated 3-year survival <20% [3]. Moreover, the
SCHOLAR-1 collaborative study showed that
prognosis of DLBCL is dismal in patients who failed
two or more lines of therapy, with an anticipated

median overall survival (OS) of 6.3 months and 1year OS rate of only 28% [4].
Chimeric antigen receptor T-cell (CAR T) therapy
has revolutionized the treatment of relapsed or refractory (R/R) LBCL, and several products targeting
CD-19 are already commercially available, namely,
axicabtagene ciloleucel (axi-cel), tisagenlecleucel, and
lisocabtagene maraleucel (liso-cel) [5e7]. These
products have demonstrated impressive complete
remission rates (CRRs) and improved OS. As a result,
efforts have recently focused on evaluating the efﬁcacy of CAR T therapies earlier in the disease course.
Three large phase III randomized studies evaluating axi-cel, tisagenlecleucel, and liso-cel in the
second line setting in LBCL against standard of care
(SOC). Consisting of platinum-based chemoimmunotherapy followed by HDT and auto-HCT
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reported outcomes in 2021 [8e10] two of these
studies namely, ZUMA-7 and TRANSFORM, on axicel and liso-cel, respectively, demonstrated superior
outcomes vis-
a-vis standard chemoimmunotherapy
followed by auto-HCT [9,11], whereas a third study,
namely, BELINDA, failed to show a therapeutic
advantage of tisagenlecleucel in this setting [10].
We analyze the outcomes of the three studies and
highlight the strengths and weaknesses associated
with their rationale and trial design. We also
extensively evaluate the reported outcomes and
discuss future applicability.

2. Traditional approach to second line
Despite advances in the frontline treatment of
LBCL, nearly 23% of patients are either primary R/R
after an initial response [12]. Since the 1990s, the
PARMA trial has established HDT followed by autoHCT as second-line treatment for eligible patients
with intermediate- and high-grade non-Hodgkin
lymphoma (NHL) who had relapse after a ﬁrst-line
anthracycline-containing regimen [2]. A total of 215
patients were enrolled in the study. All patients
received two cycles of dexamethasone, cisplatin, and
cytarabine (DHAP) salvage chemotherapy. Patients
who achieved CR or PR were randomized to autoHCT or conventional treatment (CT) consisting of
four additional cycles of DHAP. The overall
response rate (ORR) to salvage DHAP was 64%,
with only 21% ORR among patients with primary
refractory disease. The remaining 109 patients were
randomized to treatment arms. The trial showed a
signiﬁcant improvement in event-free survival (EFS)
(46% vs 12%, P ¼ 0.001) and OS (53% vs 32%,
P ¼ 0.038) in the auto-HCT arm compared to CT.
None of the patients assigned to the CT arm died of
toxic effects of treatment, whereas the death rate in
the auto-HCT arm was approximately 6% [2]. This
trial showed that auto-HCT signiﬁcantly improves
survival as second-line therapy in patients with
LBCL and established its role in this setting.
The Collaborative Trial in Relapsed Aggressive
Lymphoma trial is a phase III trial that compared
three cycles of rituximab, ifosfamide, carboplatin,
and etoposide (R-ICE) to three cycles of R-DHAP
followed by auto-HCT in patients with LBCL who
achieved CR or PR. All patients were refractory to or
relapsing after a ﬁrst-line anthracycline-containing
regimen [1]. The ORR to salvage chemotherapy was
similar in both arms, 63.5% (R-ICE) vs 62.8% (RDHAP). The 3-year EFS and OS were not signiﬁcantly different between the treatment arms, 26%
and 35% ( p ¼ 0.6) and 47% and 51% ( p ¼ 0.4), with
R-ICE and R-DHAP, respectively. The same rates of

febrile neutropenia occurred with both regimens
(16%), while patients in the R-DHAP arm had a
higher proportion of grade 4 renal toxicities [1]. A
third regimen, gemcitabine, dexamethasone, and
cisplatin (GDP) was compared to salvage DHAP in
the LY.12 trial [13]. GDP was non-inferior to DHAP,
whereby both regimens had similar response rates
(45.2% vs 44%, P ¼ 0.005). Moreover, comparable
rates of auto-HCT, EFS, and OS were observed in
both arms. GDP was associated with less toxicity,
particularly a lower frequency of febrile neutropenia
(9% vs 23%; p < 0.001). Thus far, no regimen has
proven to be clearly superior, and the choice of a
particular regimen depends on patients’ comorbidities and associated toxicity proﬁles.
Despite improved survival with HDT and autoHCT, almost half of patients with LBCL do not
respond to chemoimmunotherapy salvage treatments and, consequently, are not eligible for autoHCT. Moreover, the outcome of patients who are
primarily
refractory
to
ﬁrst-line
chemoimmunotherapy is poor. In the SCHOLAR-1 trial,
patients refractory to at least one line of treatment
had poor ORR and CRR of 36% and 7%, respectively. The 2-year OS was only 20% before availability of CAR T [4]. These data highlight the need
for novel treatments to improve patient outcomes,
particularly in refractory cases.

3. CAR T-cell therapy
 Efﬁcacy of CAR T therapy beyond second line
Currently available CAR T products for the
management of diffuse LBCL (DLBCL) and highgrade B-cell lymphoma are axi-cel, tisagenlecleucel,
and liso-cel. All three products target CD-19. Axi-cel
has a CD28 co-stimulatory domain, whereas both
liso-cel and tisagenlecleucel have a 4-1BB co-stimulatory domain. Both co-stimulatory domains provide effective signaling following CD-19 binding to
its receptors. Nevertheless, CD28 leads to a more
brisk CAR T expansion but with relatively limited
CAR T persistence. Alternatively, 4-1BB causes
gradual expansion of the CAR T, leading to a purportedly longer CAR T persistence [14]. The liso-cel
manufacturing process differs from two other
products by selecting CD8þ and CD4þ during Tcell apheresis, followed by an independent
manufacturing process for each T-cell subset [15].
Axi-cel was evaluated in the ZUMA-1 phase II
trial, including 101 patients with DLBCL, primary
mediastinal large B-cell lymphoma, and DLBCL
transformed from indolent NHL (t-iNHL). The ORR
was 83%, with a CRR of 58%. The 2-year OS was
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50.5%. For side effects, grade 3 or higher cytokine
release syndrome (CRS) and neurological events
(NE) were reported in 11% and 32% of patients,
respectively [16]. Long-term data presented at the
American Society of Hematology annual meeting
2021 showed that, after a median follow-up of 51.1
months, the median OS was 25.8 months, with
42.6% of the patients alive after 5 years. The median
EFS was 5.7 months, with a 24-month EFS rate of
38% [17]. ZUMA-1 results granted axi-cel approval
for treatment of R/R LBCL after two or more lines of
treatment in October 2017.
Tisagenlecleucel was evaluated in the JULIET
phase II trial in 111 patients with DLBCL not otherwise speciﬁed, DLBCL transformed from follicular
lymphoma (t-FL), and double- or triple-hit B-cell
lymphomas who received two or more prior lines of
therapy. The ORR was 52%, and the CRR was 40%. At
1 year, OS was 49% in all patients and higher in patients who achieved CR with an estimated OS of
approximately 80% [6]. With longer follow-up (median, 40.3 months), the ORR was 53% (95% conﬁdence interval (CI), 43.5e62.4) with a CRR of 39%.
The median PFS and OS were 2.9 and 11.1 months,
respectively. In a post hoc analysis, PFS and OS were
not reached for patients who achieved CR. In terms of
safety proﬁle, the most common grade 3e4 side effects were cytopenias, mainly anemia (39%) and
neutropenia (34%). Grade 3e4 CRS and NE developed in 23% and 11% of patients, respectively. No
treatment-related deaths were reported [18]. Moreover, 60% of patients had sustained response at 5
years [19]. The results of the JULIET study led to the
approval of tisagenlecleucel for R/R LBCL after two
or more lines of systemic therapy in May 2018.
Liso-cel was evaluated in the TRANSCEND-NHL001 trial in 269 patients with DLBCL, primary
mediastinal large B-cell lymphoma, DLBCL t-iNHL,
and follicular lymphoma grade 3B. The ORR was
73%, and the CRR was 53% [7]. At a median followup of 24 months, the median OS, PFS, and duration of response (DoR) were 27.3, 6.8, and 26.1
months, respectively [20]. The most common grade
3 or higher toxicities were cytopenias (neutropenia,
60%; anemia, 42%; and thrombocytopenia, 27%).
Moreover, grade 3 or more CRS or NE were noted in
2% and 10% of patients, respectively. Based on this
study, liso-cel was the third CAR T product
approved for the treatment of R/R LBCL beyond
second line in November 2020.
All three trials used ﬂudarabine and cyclophosphamide as the preferred regimen for lymphodepletion prior to CAR T infusion. The JULIET trial
also allowed bendamustine as a lymphodepleting
strategy in approximately 20% of patients [6].
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Long-term efﬁcacy and safety data conﬁrm CAR T
as an effective therapeutic option for patients with
R/R LBCL [16e18]. Real-world data validated these
ﬁndings. A retrospective study assessing the outcomes of patients with DLBCL treated with CAR T
therapy compared to alternate therapies showed an
improved PFS and OS with CAR T therapy. Moreover, the CRR was signiﬁcantly improved with CAR
T therapy (52% vs 22%; p < 0.001) [21]. In a retrospective analysis, the outcomes of patients enrolled
in the ZUMA-1 pivotal trial were compared to those
in the retrospective SCHOLAR-1 study. The median
OS survival was sixfold higher in patients in ZUMA1 (31 months) compared to those in SCHOLAR-1
(5.4 months), with a 73% reduction in risk of death
(hazard ratio (HR), 0.27; 95%CI, 0.00e0.38) [22].
Altogether, these results emphasize the efﬁcacy of
CAR T in the third line and beyond and provided
the basis to explore CAR T in the second-line
setting, especially in patients with primary refractory disease or early relapse who are expected to
have poor outcomes even with HDT and auto-HCT.
 CAR T in the second-line setting
Based on the positive results demonstrated in the
third line and beyond, CD19 CAR T were evaluated
in the second-line setting in three distinctive phase
III trials. All three studies included patients potentially eligible for auto-HCT and who have chemorefractory disease, deﬁned as primary refractory or
relapsing within 12 months after ﬁrst-line treatment
(Table 1). ZUMA-7 (NCT03391466) used axi-cel,
TRANSFORM (NCT03575351) used liso-cel, and
BELINDA (NCT03570892) used tisagenlecleucel.
The primary endpoint of these three trials was EFS,
albeit with slightly different deﬁnitions. Stable disease (SD) was considered an event at week 21 in
ZUMA-7, while TRANSFORM and BELINDA
considered it as an event even earlier, at weeks 12
and 9, respectively. These differences in EFS deﬁnition might have affected the ﬁnal results as
ZUMA-7 allowed in theory more time for CAR T to
demonstrate efﬁcacy, whereas BELINDA might
have had an earlier decision timepoint for deﬁning
lack of CAR T efﬁcacy, by week 9. The long-term
follow-up of the JULIET trial showed that ﬁve of
eight patients who achieved SD by 3 months converted to CR after 6, 9, and 12 months showing the
continued efﬁcacy of CAR T beyond week 9 [18].
In the ZUMA-7 trial, 180 patients were enrolled in
the axi-cel arm, of whom 170 received the product
and 179 patients were included in SOC arm [11].
The ORR was signiﬁcantly higher in the CAR T arm
(83% vs SOC 50%, p < 0.001), and a higher CRR was
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Table 1. Characteristics of patients enrolled in second-line CAR T-cell therapy trials.
Patients characteristics

ZUMA-7 [8]

TRANSFORM [9]

BELINDA [10]

N ¼ 180

N ¼ 184

N ¼ 322

CAR T product
Median age, years (range)
Patients >65 years, %
Patients who received TT
CAR T arm, %
SOC arm, %
HGBCL/double/triple hit
(CART/SOC), %
ABC subtype (CAR T/SOC), %
Stage III/IV, %
Primary refractory
Relapse within 12 months of
ﬁrst-line treatment
Progressive disease at the time of
CAR T cell therapy
Bridging therapy allowed
Bridging therapy

Axicabtagene ciloleucel
58 (21e80)
30%

Lisocabtagene maraleucel
58 (26e75)
N/A

Tisagenlecleucel
59.5 (19e79)
31.10%

94%
36%
17/15%

97%
46%
23/24%

96%
32%
19.8/11.9%

9/5%
79%
74%
26%

N/A
N/A
73%
27%

32/26.2%
64%
66%
34%

1%

N/A

26%

No
Glucocorticoid only

%
Median time from leukapheresis
to CAR T cell infusion, days
Crossover

36%
29

Yes
RDHAP, RICE, and RGDP
1 cycle
63%
31

Optional
RDHAP, RICE, RGemOx,
and RGDP
83%
54

Primary endpoints
EFS, start time point
EFS deﬁnition

Not allowed
Patients who did not respond to
SOC received CAR T
EFS
Randomization

Allowed

Allowed

EFS
Randomization

EFS
Randomization

1) Disease progression

1) Disease progression

1) SD or PD at or after
week 12

2) Death from any cause

2) Death from any cause

2) Death (any time)

3) Star of new therapy

3) Start of new therapy

4) SD as best response within
150 days from randomization

4) Not achieving CR/PR
by 9 weeks

Abbreviations: N, number; N/A, not available; CAR, chimeric antigen receptor; TT, treatment; SOC, standard of care; HGBCL, highgrade B cell lymphoma; EFS, event-free survival; RDHAP: rituximab, dexamethasone, cisplatin, cytarabine; RICE, rituximab, ifosfamide,
carboplatin, etoposide; RGDP, rituximab, gemacitabine, dexamethasone, cisplatin; RGemOx, Rtituximab, gemcitibine, oxaliplatin; CR,
complete remission; PR, partial response; SD, stable disease; PD, progressive disease.

observed in the axi-cel arm (65%) compared to the
SOC arm (32%). After a median follow-up of 24.9
months, median and 24-month EFS were signiﬁcantly improved in the axi-cel arm (8.3 months and
41%) compared to the SOC arm (4.5 months and
16%), respectively (HR, 0.40; 95% conﬁdence interval (CI), 0.31e0.51, p < 0.001). A trend toward
improved OS was observed in the axi-cel group (not
reached) versus the SOC group (35.1 months) (HR,
0.73; 95%CI, 0.53e1.01, P ¼ 0.54) (Table 2). This trial
led to the approval of axi-cel for the treatment of
patients with LBCL refractory to ﬁrst-line chemoimmunotherapy or relapsed within 12 months of the
end of ﬁrst-line treatment on April 1, 2022.
The TRANSFORM trial included 184 patients.
ORR and CRR were signiﬁcantly higher in the

CAR T compared to the SOC arm (79% and 61% vs
44% and 36%, p < 0.0001). Moreover, second-line
CAR T signiﬁcantly prolonged EFS compared to
SOC (median, 10.1 vs 2.3 months, respectively,
p < 0.0001). OS was not reached in the CAR T arm
and was 16.4 months in the SOC group ( p ¼ 0.0257)
(Table 2).
The BELINDA trial failed to show a beneﬁt of CAR
T, namely, tisagenlecleucel. It included 322 patients.
The ORR and CRR were similar in both arms (46%
and 28.4% with CAR T vs 42% and 27.5% with SOC,
respectively). The study did not meet its primary
endpoint as EFS was comparable in both arms (HR,
1.07; 95% CI, 0.82e1.40, p ¼ 0.61) (Table 2).
In terms of safety data, CRS was more frequent in
the ZUMA-7 trial, as noted in 92% of cases. This was

16.4

20%
1%

0.73 0.53e1.01 0.054

0.31e0.51 <0.001
0.4

50%
32%
2
52%
32.1

83%
65%
8.3
61%
NR
92%
6%
60%
21%

25

Median follow-up,
months
ORR
CR rate
mEFS, months
2-year OS, %
mOS, months
CRS, any grade
CRS, grade 3e4
NE, any grade
NE, grade 3e4

Abbreviations: CAR, chimeric antigen receptor; SOC, standard of care; CI, conﬁdence interval; ORR, overall response rate; CR, complete response; EFS, event-free survival; OS,
overall survival; CRS, cytokine release syndrome; NE, neurologic events.
*Estimated as original manuscript reported incidence in one patient.

NR

42%
28%
3
<0.0001
<0.0001
<0.0001

86%
66%
10.1
N/A
NR
49%
1%*
12%
4%
<0.001

6.2

48%
39%
2.3

95% CI
P-value CAR T arm SOC arm HR
(N ¼ 92)
(N ¼ 92)
95% CI
N ¼ 359

CAR T arm SOC arm HR
(N ¼ 180)
(N ¼ 179)

ZUMA-7 [8]

Table 2. Summary of responses and adverse events in the ZUMA-7, TRANSFORM, and BELINDA trials.

46%
28%
0.349 N/A
3
Not reached
0.509 0.258e1.004 P ¼ 0.0257 NR
61.30%
5.20%
10.30%
1.90%

10

N ¼ 322

CAR T arm SOC arm HR
(N ¼ 162)
(N ¼ 160)

N ¼ 184

P-value

BELINDA [10]
TRANSFORM [9]

95% CI

1.07 0.82e1.40 0.61

P-value
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followed by 61% in the BELINDA trial and 49% in
the TRANFORM trial. Grade >2 CRS showed a low
incidence in all three clinical trials (Table 2).
ZUMA-7 had the highest rate of NE (60%) with
21% grade 3e4 NE, followed by TRANSFORM (12%,
with 4% grade 3e4) and BELINDA (10.3%, with 2%
grade 3e4). Overall, adverse events were similar to
those observed in previous CD19 CAR T pivotal
trials [17,18,20]. The safety proﬁle favored the
experimental arm in all three trials, particularly
pertaining to incidence of febrile neutropenia,
thrombocytopenia, and gastrointestinal toxicity.
Furthermore, the quality of life (QoL) and patient
reported outcomes (PRO) were signiﬁcantly better
in the CAR T arms in ZUMA-7 and TRANSFORM
trials. Axi-cel resulted in signiﬁcantly improved QoL
and PRO in terms of physical functioning, global
health status, and visual analog scale by day 100
( p < 0.0001) [8]. Similarly, the TRANSFORM trial
showed that PRO, mainly cognitive function and
quality of life, was more improved compared to
SOC in patients who received liso-cel. QoL was
either improved or maintained after liso-cel [23].
ZUMA-7 and TRANSFORM trials showed positive results with signiﬁcantly improved EFS
compared to SOC. This was not the case for the
BELINDA trial as tisagenlecleucel failed to show a
similar beneﬁt of CAR T therapy in the second line
compared to auto-HCT.
The three aforementioned trials differed in
design, allowance of bridging therapy, follow-up
duration, permitting crossover, and some endpoints
deﬁnitions, which are summarized in Table 1. An
important difference worth mentioning among
these trials is allowing (or not) bridging therapy.
ZUMA-7 did not allow bridging chemotherapy,
which might have led to excluding patients with
rapidly progressing or bulky disease, whereas
TRANSFORM allowed one cycle and BELINDA
allowed several rounds of bridging chemotherapy.
Consequently, the latter trials might have included
more patients with rapidly progressing or bulky
disease. Patients who progressed after randomization did not receive axi-cel in the ZUMA-7 trial,
whereas BELINDA included 26% of patients who
had progressive disease at randomization. Additionally, the median time from leukapheresis to
CAR T infusion was shorter in the ZUMA-7 and
TRANSFORM trials (29 and 31 days, respectively)
and almost twofold longer in the BELINDA trial (54
days). In fact, data have shown that patients who
require bridging chemotherapy tend to have shorter
PFS (3.4 months) compared to patients who do not
(7.3 months) ( p ¼ 0.01) [24]. We speculate that these
differences in design could have possibly affected
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the results of the studies as requirement for
bridging therapy may be considered an indicator for
a more aggressive disease. This could represent a
selection bias in the ZUMA-7 trial, which might
have selected patients with less aggressive disease
that were probably destined to have better outcomes. Moreover, Bommier et al. did a reconstruction of individual patient data from published
ﬁgures, EFS curves showed that the BELINDA trial
perhaps included patients with more aggressive
disease in the CAR T arm [25]. Furthermore, less
than half of patients included in the SOC arm
received auto-HCT, being only 32% in BELINDA,
36% in ZUMA-7, and 42% in TRANSFORM. This
further shows the difference in the patient population among the three trials and suggests that the
population ultimately assigned to the CAR T arm in
the BELINDA trial might have had a more aggressive disease.
The median follow-up duration was longer in the
ZUMA-7 study. There was a trend toward
improvement in OS; however, it was not statistically
signiﬁcant. A longer follow-up is needed to better
understand the impact of second-line axi-cel on OS.
Most patients included in the three trials were of
white race, denoting the underrepresentation of
minorities. This certainly limits, in theory, the ability
to generalize these results to the minority
population.
Recently, a phase II, single-arm, multicenter
trial, ZUMA-12, showed the beneﬁt of axi-cel in
what was described as “ﬁrst-line” setting [26]. The
trial included 40 patients with high-risk DLBCL,
deﬁned as double- or triple-hit lymphoma or with
an international prognostic index of three or above,
who remained positron emission tomography positive (PETþ) following two cycles of chemoimmunotherapy with anthracycline-containing
regimen. The ORR was 89% (33/37), and CRR was
78% (29/37). The median DoR, EFS, and PFS were
not reached. The 1-year EFS and OS were 72.5% and
90.6%, respectively. Safety data were in line with
previous axi-cel studies with 8% and 23% incidence
of grade3 CRS and NE, respectively [26]. We
question whether this therapeutic strategy can be
deﬁned as “ﬁrst-line” or is perhaps more of a second
line; nevertheless, these data are deﬁnitely promising, further emphasizing the efﬁcacy of CAR T in
patients with high-risk LBCL.

4. Conclusions and future directions
With the results of these trials, the main question
on the future management of second-line LBCL
with the addition of CAR T into this space remains.

Future directions will likely be inﬂuenced by a
better understanding of the intricacies of the results
of these phase III clinical trials, speciﬁcally given the
differences in EFS deﬁnitions, bridging therapies,
and crossover designs as previously discussed.
Moreover, it will be important to discern outcomes
based on remission status attained prior to CAR T.
A recent observational registry study from the
Center for International Blood and Marrow Transplant Research demonstrated the beneﬁt of autoHCT versus CAR T therapy in patients in PR [27].
An important consideration pertains to time to
administer CAR T therapy. The timeline from
identifying patients with disease indication to CAR
T treatment can be inﬂuenced by several factors,
including manufacturing time and aggressive disease biology, which may require bridging therapy.
This is also important given the variation in time
from enrollment to CAR T infusion in all three
phase III studies and ZUMA-7 clinical trial not
allowing bridging therapy nor crossover, while
TRANSFORM and BELINDA allowed both bridging
therapy and crossover [9e11].
One strategy is to reduce time to CAR T
infusion centers around manufacturing. Novartis is
currently studying autologous CD-19 CAR T product YTB323 (NCT03960840), produced via an
enhanced manufacturing process. Similar enhanced
manufacturing platforms are being investigated by
Bristol Myers Squibb using the NEX-T platform for
both CD-19 and BCMA-directed autologous CAR T
products (NCT04231747, NCT04394650).
Efforts to improve efﬁcacy of autologous CAR T
therapies are evaluating a multitargeted approach in
addition to CD19. Some targets being evaluated in
clinical trials include CD22 and CD79b, among
others (NCT04723914, NCT04877080, NCT05388695,
NCT04429438). We anticipate that if they demonstrate added efﬁcacy vis-
a-vis CD19 CAR Ts in the
R/R setting, they may eventually make their way
into being evaluated in the second-line setting.
The development of allogeneic or “off the shelf”
CAR T (allo-CAR) products is also an important
strategy to limit time to CAR T infusion [28]. AlloCAR is being developed using T lymphocytes
collected from healthy donors. Allo-CAR would
provide a more readily access to the product, circumventing delays in securing apheresis and
avoiding the long manufacturing time associated
with autologous CAR T production. Infusion of allodonor T-cell products raises concerns for the
development of graft-versus-host disease (GVHD)
and rapid elimination of T cells by host immune
system, potentially limiting persistence and efﬁcacy.
These concerns have been addressed through the
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use of gene editing, which aims to disrupt or eliminate the ab T-cell receptor, thus abrogating GVHD
risk. Common examples of this include disrupting
the gene encoding for the T-cell receptor constant a
chain (TRAC ) [29]; gene editing utilized to enhance
CAR T persistence, including CD52 knockout [30];
disruption of major histocompatibility complex class
I molecules (by knocking out the b2-microglobulin
gene [B2M]) [31]; and addition of a natural killer cell
inhibitor [32]. Few studies in allo-CAR directed
against CD-19 are ongoing in early-phase clinical
trials, with results from these studies eagerly
anticipated.
We strongly believe that future clinical trials
should focus on enrolling a diverse population of
patients to ensure a good representation and guarantee reproducibility in the real-life setting across
various racial and ethnic groups. Efforts should also
be focused on lowering the high cost of these CAR T
products to make it affordable to patients in developing countries.
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